Early antibody trial for sick kids with COVID-19 halted
NCT ID NCT05092581
Summary
This early-stage study tested a single dose of lab-made antibodies (casirivimab+imdevimab) in children hospitalized due to COVID-19. The main goals were to see how long the drug stayed in their blood and to check for safety issues. The study was terminated early and only enrolled two participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Le Bonheur Children's Hospital
Memphis, Tennessee, 38103, United States
-
State University of New York at Stony Brook
Stony Brook, New York, 11794, United States
Conditions
Explore the condition pages connected to this study.